GSK PLC Sponsored ADR (NYSE:GSK – Get Free Report) has been assigned a consensus recommendation of “Hold” from the nineteen analysts that are covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, thirteen have issued a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $56.30.
A number of analysts have recently commented on GSK shares. HSBC reissued a “hold” rating on shares of GSK in a research note on Thursday, September 10th. Deutsche Bank reaffirmed a “neutral” rating on shares of GSK in a research note on Tuesday, September 29th. Wolfe Research began coverage on GSK in a report on Friday, October 9th. They set an “outperform” rating and a $70.00 price objective on the stock. Wall Street Zen cut shares of GSK from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Finally, Sanford C. Bernstein reissued a “buy” rating on shares of GSK in a report on Sunday, August 2nd.
Get Our Latest Stock Analysis on GSK
Institutional Investors Weigh In On GSK
GSK Stock Down 1.3%
Shares of NYSE:GSK opened at $48.60 on Friday. The company has a current ratio of 0.86, a quick ratio of 0.56 and a debt-to-equity ratio of 1.18. The company has a fifty day simple moving average of $49.32 and a 200 day simple moving average of $52.38. The firm has a market cap of $98.31 billion, a PE ratio of 10.37, a price-to-earnings-growth ratio of 2.21 and a beta of 0.29. GSK has a 12-month low of $45.81 and a 12-month high of $61.69.
GSK Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, January 7th. Investors of record on Friday, November 13th will be issued a dividend of $0.4518 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $1.81 annualized dividend and a yield of 3.7%. This is an increase from GSK’s previous quarterly dividend of $0.4515. GSK’s payout ratio is 61.81%.
About GSK
GSK plc is a global biopharmaceutical company headquartered in the United Kingdom. It researches, develops and manufactures medicines and vaccines, with a focus on areas including infectious diseases, HIV, respiratory and immune conditions, and cancer. Its products include vaccines such as Shingrix, which helps prevent shingles, and Arexvy, for respiratory syncytial virus (RSV). GSK also makes specialty medicines, including treatments for HIV and respiratory diseases, and continues to develop new medicines and vaccines through its research programs.
Featured Articles
- Five stocks we like better than GSK
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
